Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells specifically [1][2][3] - The company is participating in upcoming investor conferences, including the Bank of America Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference, to engage with investors [2] Company Overview - Perspective Therapeutics specializes in developing advanced treatments for various cancers and is advancing its proprietary technology for targeted radiation therapy [1][2] - The company is also working on complementary imaging diagnostics that utilize the same targeting moieties, enhancing the personalization of treatment and optimizing patient outcomes through a "theranostic" approach [2][3] Clinical Development - The company's current clinical programs include melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359), which are in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Company Overview - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on pioneering advanced treatments for cancers throughout the body using proprietary technology that utilizes the alpha-emitting isotope 212Pb [2] - The company is developing complementary imaging diagnostics that incorporate the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Current Developments - The company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. for treating metastatic melanoma and neuroendocrine tumors [3] - Perspective Therapeutics is expanding its regional network of drug product finishing facilities, supported by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations [3] Upcoming Events - The company will report its first quarter 2025 financial results and provide a business update on May 12, 2025, after the market closes [1]